English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Prostate Health Index (phi)
An FDA approved, CE marked blood test analysis to be used as an aid in distinguishing prostate cancer from benign prostatic conditions1
phi is a proprietary calculation developed by Beckman Coulter Inc. that uses a combination of three blood tests to produce a "phi score." This phi score provides more information about what elevated PSA levels might mean and the probability of finding prostate cancer on biopsy.*
-
This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.
Video Here's What You Need to Know About phi
Why choose phi? Learn more by watching this video.
Watch now
Announcement "Is it Cancer?"
Provide diagnostic clarity. Assess the probability of prostate cancer with phi.
Journal Article Clinical Utility of the Prostate Health Index (phi) for Biopsy Decision Management in a Large Group Urology Practice
Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are typically found to be benign. The Prostate Health Index (phi) exhibits significantly improved diagnostic accuracy for prostate cancer detection when compared to tPSA and %fPSA1
Read article 
Brochure The phi Clinical Summary
The superior performance of phi compared to PSA alone has been demonstrated through multiple peer-reviewed publications. Read summaries of the articles and discover the power of phi.
Download1Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol, 2015; 193(4):1163-9.
2Jay White B, Vittal Shenoy, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-017-0008-7.
3Beckman Coulter Access Hybritech p2PSA Instructions for Use.
*phi results are intended to be used as an aid in distinguishing prostate cancer from benign prostatic conditions in men 50 years of age and older with total PSA results in the 2-10 ng/mL range and negative digital rectal examination DRE findings.
†Beckman Coulter, the stylized logo, and phi are trademarks or registered trademarks of Beckman Coulter, Inc
‡Biopsy outcomes of patients in the 4-10 ng/mL range.
